Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00902291 · ClinicalTrials.gov registry record · Phase 2
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Phase 2 study of Pancreatic Cancer and Carcinoma, Pancreatic Ductal, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 205
- Enrollment target
- 20
- Study locations
NCT00902291 is a Phase 2 study of Pancreatic Cancer and Carcinoma, Pancreatic Ductal that has completed, run by Astellas Pharma. The registered enrollment target is 205 participants, below the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT00902291, a Phase 2 study of Pancreatic Cancer and Carcinoma, Pancreatic Ductal, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 205 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study to evaluate AGS-1C4D4 administered in combination with Gemcitabine chemotherapy in subjects with Metastatic Pancreatic Cancer.
Conditions Studied
Interventions
- BIOLOGICAL AGS-1C4D4
- BIOLOGICAL Gemcitabine
Study Locations (20)
Florida
- Palm Beach Institute of Hematology and Oncology - Boynton Beach
- University of Miami - Miami
New York
- Memorial Sloan Kettering Cancer Center - New York
- Regional Oncology Center - Syracuse
Tennessee
- Baptist Regional Cancer Center - Knoxville
- Vanderbilt University Medical Center, Div. of Medical Oncology - Nashville
Ontario
- Juravinski Cancer Centre - Hamilton
- Sunnybrook Health Sciences Centre - Toronto
Other
- Chu Estaing - Clermont-Ferrand
- Centre Jean Bernard, Oncologie médicale - Le Mans
California
- University of California San Diego Medical Center - La Jolla
Louisiana
- Medical Oncology LLC - Baton Rouge
Maryland
- Annapolis Oncology Center - Annapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2009-04 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00902291
The ClinicalTrials.gov registry entry for NCT00902291 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (48% lower). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which AGS-1C4D4 is the first listed.
NCT00902291 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, New York, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00902291 about?
NCT00902291 is a clinical study titled "A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer". A study to evaluate AGS-1C4D4 administered in combination with Gemcitabine chemotherapy in subjects with Metastatic Pancreatic Cancer.
What is the current status of trial NCT00902291?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 205 participants. The study started on 2009-04. Estimated completion is 2012-04.
What conditions does trial NCT00902291 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Carcinoma, Pancreatic Ductal, Pancreatic Disease.
What interventions are being tested in trial NCT00902291?
The interventions under investigation include: AGS-1C4D4 (BIOLOGICAL), Gemcitabine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00902291?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00902291 being conducted?
This trial has 20 study locations across California, Florida, Louisiana, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.